American Journal of Kidney Diseases
Volume 44, Issue 6 , Pages 941-949, December 2004

Effect of dialysis modality on plasma fibrinogen concentration: A meta-analysis

Presented at the 35th Annual Meeting of the American Society of Nephrology, Philadelphia, PA, November 3, 2002.

  • Philip Goldwasser, MD

      Affiliations

    • Department of Medicine, Veterans Affairs New York Harbor Healthcare Center, Brooklyn, NY
    • Corresponding Author InformationAddress reprint requests to Philip Goldwasser, MD, VA NY Harbor Healthcare Center-Brooklyn, 800 Poly Pl (111-F), Brooklyn, NY 11209
  • ,
  • Joseph G. Feldman, DrPH

      Affiliations

    • Department of Preventive Medicine and Community Health, State University of New York Downstate Medical Center, Brooklyn, NY
  • ,
  • Mingiziem Emiru, MD

      Affiliations

    • Department of Medicine, Veterans Affairs New York Harbor Healthcare Center, Brooklyn, NY
  • ,
  • Robert H. Barth, MD

      Affiliations

    • Department of Medicine, Veterans Affairs New York Harbor Healthcare Center, Brooklyn, NY

Received 15 April 2004; accepted 26 August 2004.

Background: Concentrations of plasma fibrinogen, a vascular risk factor, tend to be greater in patients on peritoneal dialysis (PD) than hemodialysis (HD) therapy, like concentrations of serum cholesterol, lipoprotein(a), and transthyretin, despite the substantial loss of protein during PD. Worse vascular outcome has been noted in PD patients compared with HD patients in several studies. Methods: In this study, the mean difference in plasma fibrinogen levels (PD − HD) was quantified by means of meta-analysis of mean differences found in 12 cohorts with both PD and HD patients (set 1; N = 630) by using a fixed-effects model and meta-analysis of mean fibrinogen values reported in 30 cohorts of patients on a single dialysis modality (set 2; 8 PD cohorts, 22 HD cohorts; N = 2,096) by using a mixed model. Results: On meta-analysis, the weighted mean difference (PD − HD) was 105 mg/dL (95% confidence interval [CI], 86 to 124 [3.1 μmol/L; 95% CI, 2.5 to 3.6]) in set 1 and 103 mg/dL (95% CI, 53 to 153 [3.0 μmol/L; 95% CI, 1.6 to 4.5) in set 2. Conclusion: Like other vascular risk factors, such as cholesterol and lipoprotein(a), plasma fibrinogen level is markedly greater in PD than HD patients, with an approximate difference of 100 mg/dL [2.9 μmol/L]. Different plasma reference ranges for fibrinogen need to be defined for PD and HD patients. The mechanism for the difference and the possible role of hyperfibrinogenemia in worsening vascular disease in PD patients deserve study.

Index words:  Fibrinogen , peritoneal dialysis (PD) , hemodialysis (HD) , meta-analysis , albumin , reference interval

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This material is based upon work supported by the Department of Veterans Affairs.

PII: S0272-6386(04)01252-1

doi:10.1053/j.ajkd.2004.08.019

American Journal of Kidney Diseases
Volume 44, Issue 6 , Pages 941-949, December 2004